NCT05101369View on ClinicalTrials.gov

A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550

PHASE1CompletedINTERVENTIONAL

Enrollment

7

Participants

Timeline

Start Date

January 21, 2022

Primary Completion Date

March 25, 2022

Study Completion Date

March 25, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

INCB086550

INCB086550 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radio labeled INCB086550.

Trial Locations (1)

LS2 9LH

Covance Leeds Cru, Leeds

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY

NCT05101369 - A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550 | Biotech Hunter | Biotech Hunter